A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer
To evaluate the efficacy and safety of Sintilimab combined with apatinib and chemotherapy as
First-line or second-line Therapy in Treatment of HER-2 negative MSS Advanced or Metastatic
GC or GEJ Cancer. At the same time, the correlation between tissue programmed death
ligand-1(PD-L1) expression and blood circulating tumor cell(CTC) counts and the efficacy of
immune combination therapy was also explored.
Participants receive Sintilizumab 200 mg, intravenously (IV) every 3 weeks(Q3W);plus Apatinib
250 mg twice daily (BID) by continous oral adminstration for 14 days, followed by a recovery
period of 7 days; plus Tegafur gimeracil oteracil potassium capsules (40mg for body surface
area < 1.25/m^2, 50mg/m^2 for body surface area 1.25-1.5m^2, 60mg for body surface area >
1.5/m^2) BID by continous oral adminstration for 14 days, followed by a recovery period of 7
days, plus Oxaliplatin 85 mg/m^2, IV Q3W; for 4-6 cycles followed by Cindilizumab plus
Tegafur gimeracil oteracil potassium capsules.
Gastric Cancer, Chemotherapy, Immunotherapy
Sintilimab 200 mg, intravenously (IV) every 3 weeks(Q3W)
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.